BMY
66
-3
JCI
51
-3
AIV
34
4
AZO
48
-2
XOM
57
-2
FIS
48
2
FE
62
2
MUR
49
2
ETN
55
-2
BWA
55
-5
KO
47
3
IRM
47
3
MO
45
-2
BLK
49
3
GLW
82
3
EMR
51
-2
SIG
67
-5
MAS
34
-4
EL
25
-2
NAVI
40
2
BMY
66
-3
JCI
51
-3
AIV
34
4
AZO
48
-2
XOM
57
-2
FIS
48
2
FE
62
2
MUR
49
2
ETN
55
-2
BWA
55
-5
KO
47
3
IRM
47
3
MO
45
-2
BLK
49
3
GLW
82
3
EMR
51
-2
SIG
67
-5
MAS
34
-4
EL
25
-2
NAVI
40
2
Financhill
Back

Sarepta Therapeutics, Inc. 10K Form

Buy
52

SRPT
Sarepta Therapeutics, Inc.

Last Price:
$23.19
Seasonality Move:
12.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $2.2B
Cash Flow: $123.2M
Price / Cash Flow: 0
Annual Sales: $10.87
Price / Book: 2.14

Profitability

EPS (TTM): -8.43820
Net Income (TTM): $-842.8M
Gross Margin: $1.3B
Return on Equity: -64.94%
Return on Assets: -23.47%

Sarepta Therapeutics, Inc. Earnings Forecast

Key Sarepta Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 30 years for SRPT is 59.78%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 22.37% of Gross Profit Margin.
  • The Research & Development expenses have been 67.92% of Revenue.
  • The Net Earning history of SRPT is -32.45% of Total Revenues.
  • Per Share Earnings over the last 30 years have been positive in 15 years.

Sarepta Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 0.91
Current Ratio: 2.32
Quick Ratio: 1.3

Price-to-Earnings

Trailing P/E Ratio: 8.11
Forward P/E Ratio: 7.64

SRPT Technical Analysis vs Fundamental Analysis

Buy
52
Sarepta Therapeutics, Inc. (SRPT) is a Buy

Is Sarepta Therapeutics, Inc. a Buy or a Sell?